Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored therapy for H. pylori in penicillin-allergic patients
NCT03708848Phase 4Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Dec 2018
- Primary completion
- Sep 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esomeprazole, bismuth subcitrate, clarithromycin, metronidazole, levofloxacin and 1 more in Helicobacter pylori infection, sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Helicobacter pylori eradication rate. Started Dec 2018; status: completed.
02
Drugs
esomeprazolebismuth subcitrateclarithromycinmetronidazolelevofloxacin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT03708848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708848.